40例新型冠状病毒肺炎患者使用洛匹那韦/利托那韦安全性分析

目的:了解洛匹那韦/利托那韦用于新型冠状病毒(SARS-CoV-2)感染患者的安全性,为新型冠状病毒肺炎(COVID-19)的临床治疗提供建议。方法:对40例新型冠状病毒病确诊患者使用洛匹那韦/利托那韦片后发生药物不良反应的类型、性质、转归等进行统计分析。结果40例患者中29例(72.5%)发生与洛匹那韦/利托那韦相关不良反应,出现2种及2种以上不良反应13例(32.5%),严重不良反应4例(10%)。不良反应类型主要有甘油三酯升高20例(50%)、恶心7例(17.5%)、腹泻7例(17.5%)等。男女组和不同年龄组间不良反应发生率无统计学差异。结论:洛匹那韦/利托那韦不良反应发生率高,严重不良反应发生率低,可在密切观察患者症状和检验指标的前提下,用于新型冠状病毒肺炎患者。

Safety analysis of lopinavir/ritonavir tablets in 40 hospitalized patients with Coronavirus Disease 2019

OBJECTIVE To investigate the safety of lopinavir/ritonavir tablets in the hospitalized patients with coronavirus disease 2019 (COVID-19) and provide insight into clinical treatment of COVID-19.METHODS The adverse drug reaction (ADR) reports from 40 diagnosed severe acute respiratory coronavirus 2 (SARS-CoV-2) infections were used for analysis of types,characteristics and outcomes of the events caused by lopinavir/ritonavir tablets.RESULTS Of the 40 patients,29 (72.5%) had lopinavir/ritonavir-related adverse reactions,13 (32.5%) had two or more adverse reactions,and 4 (10%) had serious adverse reactions.The main types of adverse reactions were elevated triglycerides in 20 patients (50%),nausea in 7 patients (17.5%),and diarrhea in 7 patients (17.5%).There was no statistically significant difference in the incidence of adverse reactions between male and female different age groups.CONCLUSION ADRs were commonly observed in patients received lopinavir/ritonavir tablets,whereas the severe ADRs remained infrequent.These findings indicate that lopinavir/ritonavir tablets can be safely used under the premise of close monitoring of patients' symptoms and test indicators.